Erratum: Vascular disrupting effect of CKD-516: Preclinical study using DCE-MRI (Investigational New Drugs (DOI 10.1007/s10637-012-9915-6));Vascular disrupting effect of CKD-516: Preclinical study using DCE-MRI

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1097-1106

  Kim, Kyung Won ^a   Lee, Jeong Min ^b,f   Jeon, Yong Sik ^b   Lee, In Joon ^c   Choi, Yoonseok ^b   Park, Jisuk ^b   Kiefer, Berthold ^d   Kim, Chin ^e   Han, Joon Koo ^b   Choi, Byung Ihn ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Seoul National University Hospital   (South Korea)

^c National Cancer Center   (South Korea)

^d SIEMENS Healthcare   (South Korea)

^e Chong Kun Dang Pharmaceuticals   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

CKD 516; DCE MRI; Tubulin; Vascular disrupting agent

Indexed keywords

CKD 516; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG TARGETING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EXPERIMENTAL RABBIT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MUSCLE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPHENONES; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS, MUSCLE TISSUE; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; TUBULIN; TUBULIN MODULATORS; VALINE;

EID: 84884816304     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0012-2     Document Type: Erratum

References (23)

1. McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116:1859-1871
2. Delmonte A, Sessa C (2009) Ave8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 18:1541-1548
3. Zweifel M, Padhani AR (2010) Perfusion mri in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 37(Suppl 1):S164-S182
4. Wang H, Marchal G, Ni Y (2011) Multiparametric mri biomarkers for measuring vascular disrupting effect on cancer. World J Radiol 3:1-16
5. Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, Nuyts J, Marchal G, Ni Y (2010) Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 20:2013-2026
6. Lee J, Bae S, Lee SH, Choi H, Kim YH, Kim SJ, Park GT, Moon SK, Kim DH, Lee S, Ahn SK, Choi NS, Lee KJ (2010) Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg Med Chem Lett 20:6327-6330
7. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, Lee CS, Kang HR, Ahn SK, Moon SK, Kim DH, Lee S, Choi NS, Lee KJ (2010) Identification of ckd-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem 53:6337-6354
8. Lunt SJ, Akerman S, Hill SA, Fisher M, Wright VJ, Reyes-Aldasoro CC, Tozer GM, Kanthou C (2010) Vascular effects dominate solid tumor response to treatment with combretastatin a-4-phosphate. Int J Cancer
9. Kidd JG, Rous P (1940) A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form. J Exp Med 71:813-838
10. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic mr imaging. 1. Fundamental concepts. Magn Reson Med 17:357-367
11. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced t(1)-weighted mri of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
12. Weidner N (1999) Tumour vascularity and proliferation: clear evidence of a close relationship. J Pathol 189:297-299
13. Jiang HJ, Zhang ZR, Shen BZ, Wan Y, Guo H, Li JP (2009) Quantification of angiogenesis by ct perfusion imaging in liver tumor of rabbit. Hepatobiliary Pancreat Dis Int 8:168-173
14. Deng ZT, Feng T, Wang P, Qi X, Chen XH, Li YX, Song CL, Geng MY, Li J (2011) Effects of the novel vascular targeting agent mds-11p on tumor vascularity and its antitumor activity. Biochem Pharmacol 82:1832-1842
15. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) Zd6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253
16. Lee TY, Gotlieb AI (2003) Microfilaments and microtubules maintain endothelial integrity. Microsc Res Tech 60:115-127
17. Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6
18. Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG (2011) A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb) 3:375-387
19. Gaya A, Daley F, Taylor NJ, Tozer G, Qureshi U, Padhani A, Pedley RB, Begent R, Wellsted D, Stirling JJ, Rustin G (2008) Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study. Br J Cancer 99:321-326
20. Lavisse S, Lejeune P, Rouffiac V, Elie N, Bribes E, Demers B, Vrignaud P, Bissery MC, Brule A, Koscielny S, Peronneau P, Lassau N (2008) Early quantitative evaluation of a tumor vasculature disruptive agent ave8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 43:100-111
21. Luo Y, Hradil VP, Frost DJ, Rosenberg SH, Gordon GB, Morgan SJ, Gagne GD, Cox BF, Tahir SK, Fox GB (2009) Abt-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs 20:483-492
22. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, Marchal G, Ni Y (2009) Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44:44-53
23. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin a4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Investig 115:2992-3006